Adamis Pharmaceuticals (NASDAQ:ADMP) investors sent the stock on a nearly 9% gain in value yesterday on back of the news of the company’s submission to the FDA of a prior approval supplement (PAS) for the pediatric version of Symjepi. With the pediatric version designed differently than the original, FBR analyst Andrew D’silva actually sees less risk circling a potential approval on ADMP’s allergy shot than the original version of the epinephrine auto-injector, a cheaper option to competitor Mylan’s EpiPen.
Story Continues
